Claritev stock
CTEVNYSEClaritev Corporation, HealthcareISIN US62548M2098
42Score 42 out of 100, Weak
Price and trend
83 / 100
Price history
−54% in one yearThe chart shows daily closes over 2 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 5.7% above it.
Since August 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 59).
The price is 54% below its 52-week high. Largest decline in 2 years: 81% (August 2025 to February 2026).
Chart figures for advanced users
- SMA 50$26.44
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$25.45
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)59
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$13.47
- The lowest closing price of the last twelve months.
- Resistance$58.62
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Claritev Corporation belongs to the Medical (Healthcare Information Services) industry (United States) and, with a market value of $455.89M, is number 24 of 25 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $965.41M (up 3.7% year on year) and a loss of $284.28M.
- MEQIRI Score 42 out of 100 (Weak): rank 517 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
None of our strength checks applies.
Weaknesses
- Interest barely coveredOperating profit covers interest only 0.1 times.Stability 21
- DilutionShare count up 40% since 2020.Capital allocation 57
- Volatile share priceVolatility 119% a year over the last 12 months.Stability 21
Its standout strength is technical analysis, while profitability and stability hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
Fairly valuedClosing price of 11 Nov 2026, used by the daily score.
No fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 6.9% on the twelve months before. Revenue has stayed largely stable since 2018.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 28%, operating 5%, net −29%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 22 Feb 2027in 102 days
- Last reported
- 9 Nov 2026EPS reported −$3.64 (expected −$3.63)in line with expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- −$15.120.0%
- Revenue
- $1.01B0.0%
- Earnings per share
- −$13.530.0%
- Revenue
- $1.06B0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +26.9%2026 guidance raised: revenue of $1.0 to $1.02 billion (up 2 percentage points), adjusted EBITDA of $610 to $620 million and free cash flow of $5 to $15 million (up $5 million).
“On the strength of Q2, we are raising our revenue guide 2 full percentage points to a new range of $1 billion to $1.02 billion, reflecting 4% to 6% growth and marking a return to greater than $1 billion of annual revenue, which we last eclipsed in 2022.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 7 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
4 insiders bought on the open market between 18 May 2026 and 9 Jun 2026, $493,445 in total. 3 insiders sold, $1.06M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Ares Management LlcPurchase
10 Nov 2026, Major holder
- Shares
- 65,579
- Price
- $26.14
- Value
- $1.71M
- Ares Management LlcPurchase
10 Nov 2026, Major holder
- Shares
- 65,579
- Price
- $26.14
- Value
- $1.71M
- Ares Management LlcPurchase
9 Nov 2026, Major holder
- Shares
- 50,000
- Price
- $24.42
- Value
- $1.22M
Show 15 more
- Ares Management LlcPurchase
9 Nov 2026, Major holder
- Shares
- 50,000
- Price
- $24.42
- Value
- $1.22M
- Ares Management LlcPurchase
26 Oct 2026, Major holder
- Shares
- 20,834
- Price
- $24.07
- Value
- $501,466
- Ares Management LlcPurchase
26 Oct 2026, Major holder
- Shares
- 20,834
- Price
- $24.07
- Value
- $501,466
- Ares Management LlcPurchase
23 Oct 2026, Major holder
- Shares
- 50,000
- Price
- $23.53
- Value
- $1.18M
- Ares Management LlcPurchase
23 Oct 2026, Major holder
- Shares
- 50,000
- Price
- $23.53
- Value
- $1.18M
- Misencik TiffaniSale
15 Oct 2026, SVP, Chief Growth Officer
- Shares
- 5,812
- Price
- $23.81
- Value
- $138,390
- Garis Douglas MichaelSale
21 Sept 2026, EVP&CFO
- Shares
- 9,025
- Price
- $30.59
- Value
- $276,075
- Dalton TravisPurchase
28 Aug 2026, Pres., CEO & Executive Chair
- Shares
- 1,950
- Price
- $38.48
- Value
- $75,040
- Dalton TravisPurchase
27 Aug 2026, Pres., CEO & Executive Chair
- Shares
- 4,500
- Price
- $38.81
- Value
- $174,623
- Misencik TiffaniSale
14 Aug 2026, SVP, Chief Growth Officer
- Shares
- 8,850
- Price
- $40.07
- Value
- $354,593
- Mintz William B.Sale
10 Aug 2026, SVP, Chief Strategy Officer
- Shares
- 8,431
- Price
- $34.24
- Value
- $288,677
- Carol NutterPurchase
9 Jun 2026, SVP, Chief People Officer
- Shares
- 875
- Price
- $28.41
- Value
- $24,856
- Prince John MichaelPurchase
19 May 2026, Board
- Shares
- 10,000
- Price
- $16.00
- Value
- $160,000
- Kim MichaelPurchase
18 May 2026, EVP, Chief Digital Officer
- Shares
- 3,000
- Price
- $16.65
- Value
- $49,950
- Dalton TravisPurchase
18 May 2026, Pres., CEO & Executive Chair
- Shares
- 20,920
- Price
- $12.36
- Value
- $258,638
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Claritev
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 42
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Healthcare Information Services)
The next larger and next smaller companies by market value
- PhreesiaPHR $795.13M55
- SOPHiA GENETICSSOPH $635.9M47
- RaySearch LaboratoriesRAY-B.ST $587.54M66
- NRC HealthNRC $570.01M59
- Evolent HealthEVH $561.28M45
- CarlsmedCARL $507.83M46
- GPIGPI.MI $480.24M44
- Surgical Science SwedenSUS.ST $320.34M66
ETFs that hold Claritev
Held by 2 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.01% | 0.30% | €4.22B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.01% | 0.30% | €2.17B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 20 Feb 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.